Drug
Sp2086
Sp2086: highest development phase Phase 1, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| SP2086 NCT02815748 | Phase 1 | Type 2 Diabetes |
Latest
No recent events.
Follow Sp2086 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.